Persistent complete donor chimerism is an important clinical indicator for remissions of hematological malignancies after HLA-matched allogeneic stem cell transplantation (SCT). However, the mechanisms mediating the persistence of complete donor chimerism are poorly understood. The frequent coincidence of complete donor chimerism with graft-versus-leukemia effects and graft-versus-host disease suggests that immune responses against minor histocompatibility antigens (mHags) are playing an important role in suppressing the host hematopoiesis after allogeneic SCT. Here, we investigated a possible relationship between donor immune responses against the hematopoiesis-restricted mHag HA-1 and the long-term kinetics of host hematopoietic chimerism in a cohort of 10 patients after allogeneic HLA-matched, HA-1 mismatched SCT. Functional HA-1 specific CTLs (HA-1 CTLs) were detectable in 6/10 patients lysing host-type hematopoietic cells in vitro. Presence of HA-1 CTLs in the peripheral blood coincided with low host hematopoiesis levels quantified by highly sensitive mHag specific PCR. Additionally, co-incubation of host type CD34 + cells with HA-1 CTLs isolated after allogeneic SCT prevented progenitor and cobblestone area forming cell growth in vitro and human hematopoietic engraftment in immunodeficient mice. Conversely, absence or loss of HA-1 CTLs mostly coincided with high host hematopoiesis levels and/or relapse. In summary, in this first study, presence of HA-1 CTLs paralleled low host hematopoiesis levels. This coincidence might be supported by the capacity of HA-1 CTLs isolated after allogeneic SCT to specifically eliminate host type hematopoietic stem/progenitor cells. Additional studies involving multiple mismatched mHags in more patients are required to confirm this novel characteristic of mHag CTLs as factor for the persistence of complete donor chimerism and leukemia remission after allogeneic SCT.
Introduction
Leukemia relapse is the main cause for mortality after HLA-matched allogeneic stem cell transplantation (SCT) [1, 2] . The overall relapse risk after allogeneic SCT is strongly influenced by the intrinsic properties of the leukemia, such as karyotype or somatic gene mutations [3, 4] . Complete donor chimerism is an important clinical indicator for remissions of hematological malignancies in individual patients after allogeneic SCT [5, 6] . Conversely, rapid expansion of the host hematopoietic cell compartment is strongly associated with relapse [5, 6] . The impact of the transplanted donor immune system on complete donor chimerism is well documented by the positive effects of donor lymphocyte infusions (DLI) [7, 8] and by the negative effects of T-cell depletion [9] . Moreover, Graft-versus-host disease (GvHD) is frequently associated with the conversion to complete donor chimerism [5, 6] . These observations suggest that T-cell responses regulating donor chimerism are directed against the same targets as those mediating graftversus-leukemia (GvL) effects and GvHD, namely minor histocompatibility antigens (mHags).
MHags are highly immunogenic polymorphic peptides derived from cellular proteins and presented in HLA-molecules [10] . Most mHags exist in two alleles based on a single nucleotide polymorphism in the encoding gene. Mostly only one allele forms immunogenic T-cell epitopes leading to strong immune responses after HLA-matched but mHag mismatched SCT [10] . MHags show a differential tissue distribution, which allows a separation of GvL effects from GvHD [11] . Namely, ubiquitously expressed mHags have been identified as the prime in situ targets of GvHD [12] . Consequently, mismatched hematopoiesis-restricted mHags might be therapeutically exploited to evoke strong GvL effects with low risk of GvHD [10] . The hematopoiesis-restricted mHag HA-1 appears particularly suitable for immunotherapeutic purposes since it is highly immunogenic [13] and its expression is shared by virtually all hematopoietic cells including normal [14] and leukemic progenitors [15, 16] , lymphoma [17] and multiple myeloma cells [18] . Only the HA-1 H but not the HA-1 R allele forms immunogenic T-cell epitopes (in HLA-A2 and -B60) [10] . Thus, HLA-matched/HA-1 mismatched SCT can evoke strong T-cell responses of the HA-1 RR donor against hematopoietic cells of the HA-1 HR/HH patient. The in vivo relevance of HA-1 in the GvL effect is documented by several observations. First, HA-1 specific cytotoxic T-lymphocytes (HA-1 CTLs) are capable of eradicating human leukemia cells in immunodeficient mice [19] . Second, HA-1 CTLs emerging after donor-lymphocyte infusions (DLI) subsequent to T-cell depleted SCT coincide with molecular remissions of relapsed CML and mutiple myeloma [20] . Finally, the leukemia relapse risk is lower in patients with GvHD subsequent to HA-1 mismatched compared to HA-1 matched allogeneic SCT [21] [22] [23] .
Since HA-1 CTLs isolated after allogeneic SCT eliminate both malignant and non-malignant host hematopoietic cells [14] [15] [16] [17] [18] 20] in vitro and in vivo, we hypothesized that a sustained immune reconstitution with HA-1 CTLs is associated with a persistently complete donor chimerism after allogeneic SCT. Here, we studied for the first time the relationship between the long-term HA-1 specific immune response and host hematopoiesis levels after T-cell replete HLA-matched, HA-1 mismatched SCT.
Materials and Methods

Subjects studied
All HLA-A2 + patients receiving an allogeneic 10/10 HLA-matched (on a high-resolution level for exon 2+3 for HLA-A, B, C and for exon 2 for HLA-DRB1 and -DQB1 according to the cur- 
Chromium release assay
Cytotoxicity was tested in a standard 4h chromium release assay as described [26] . In short, 2500 51 Cr-labeled target cells were incubated with serial dilutions of effector CTLs for 4 hours; supernatants were harvested for gamma counting: % specific lysis = (experimental releasespontaneous release)/(maximal release-spontaneous release) x 100%.
Quantification of host chimerism
Detection of Y-chromosome pos and HA-1 H chimeric cells was performed on PBMCs as described earlier [27] . In short, the DNA was isolated with the QIAamp DNA blood minikit (Qiagen, Leusden, The Netherlands). Y-chromosome specific chimerism was analyzed using a onestep real-time PCR protocol. A second PCR reaction detecting the human Hematopoietic Cell Kinase gene (HCK) was carried out in parallel to standardize the data. Detection of HA-1 H chimeric cells was performed using a nested PCR protocol. Amplification data were collected and analyzed with the MyiQ TM Single-Color real-time PCR detection system (Bio-Rad Laboratories, Veenendaal, The Netherlands). The data are expressed as normalized fold expression, which was calculated according to the corresponding HCK levels. All samples were tested in at least two separate tests. A titration series of a mHag pos EBV LCL Cell Line [11] 
Liquid HPC and HALO assays
HPC assays were performed as described by the manufacturer (StemCell Technologies Inc., Grenoble, France). In short, 1000 BM-or 200 UCB-derived CD34 + or CD133 + cells (supplemented with CTLs or not) were cultured in 1.1 ml Methocult dispensed in 35-mm dishes (Greiner, Alphen a/d Rijn, The Netherlands) for 14 days at 37°C, 5% CO 2 . The number of erythroid, granulocyte and monocyte colonies was expressed as number of colonies formed per plate using an inverted light microscope. The HALO-96 human assay was used to detect human progenitor cell proliferation in mouse BM as described by the manufacturer (HemoGenix, Colorado, USA). Briefly, 1,25x10 5 BM WBC/well were plated in a 96-wells plate and incubated at 37°C, 5% CO 2 for 6 days with HPC specific cytokine mix (HemoGenix). Intracellular ATP content served as substrate for a luciferin/luciferase reaction was measured as relative light units (RLU) (Centro LB 960 luminometer, Berthold Technologies, Vilvoorde, Belgium) and was determined exactly based on an ATP standard curve included into the assay.
Cobblestone area forming cell assay
Irradiated (500 rad) 2.7x10 4 x10 4 NIH3T3 mouse fibroblasts in IMDM supplemented with 10%
FCS were added to a 96 well flat bottom plate pre-coated with 1% gelatin. The next day, fibroblasts were overlain with the CD34 + cells obtained from the overnight incubation with CTLs or medium. Subsequently, the cells were cultured at 37°C in 5% CO 2 ; medium was replenished weekly by exchanging half of the medium with fresh CAFC medium. After 5 weeks, wells were scored positive if at least one phase-dark hematopoietic clone (a cobblestone area of at least 4 cells) was observed.
NOD/SCID repopulation experiments
8-10 weeks old female NOD.CB17-prkdc<scid>/J (NOD/SCID) mice (Charles River, France) were used after ethical approval by the Leiden University Medical Center review board on animal studies (Permit Number: 08189). 24 hours after sublethal irradiation with 3.5 Gy, NOD/ SCID mice received a tail injection with 2x10 5 CD34 + cells pre-incubated overnight in a sterile FACS tube with irradiated CTLs (5D5, 3HA15 and MBM13) at an effector to target ratio of 7:1. Three UCBs were used with 3-4 mice per group for each UCB. Mice were sacrificed after 14 and 16 weeks. Cell suspensions (BM and spleen) and peripheral blood were prepared and analyzed by flow cytometry as described [19] .
Statistical Analysis
Statistical analysis was performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). A p-value < 0.05 was considered statistically significant.
Results
Kinetics of HA-1 CTL responses after allogeneic SCT
Ten patients transplanted with SC grafts of HLA-matched, HA-1 mismatched donors were included in this study. The patient characteristics are shown in Table 1 and detailed clinical information is provided in S1 Appendix. The median observation time post transplant was 613 days (range 125-1162). Presence of HA-1 CTLs was analyzed in donor PBMCs obtained prior to SC collection and in all available patient PBMC samples before and after allogeneic SCT. None of 8 evaluable SC donors showed HA-1 CTLs in the peripheral blood before SCT. Post-transplant patient's samples collected at 18 (median; range 9-36) post-transplant time points per patient with a median interval of 15 days (median; range 5-250) were analyzed. HA-1 CTLs were detectable in 6/10 patients (patients 1-6) after SCT with frequencies between 0.02% and 0.14% of the viable CD3 + /CD8 + Tcells. HA-1 CTLs were first detected 72 days (median; range 28-195) after allogeneic SCT (Fig. 1) . Increment of HA-1 CTLs was detectable 26 days (median; range 11-70) after discontinuation of CsA, MMF or prednisolone (patient 1,2, 4-6), 19 days (median; range 0-69) after onset of acute or chronic GvHD (patients 3-6) and 46 days after the last DLI (patient 5). Additional HA-1 CTL peaks were found during the course of GvHD (patient 3). HA-1 CTLs were observed until day 516 (median; range 125-699) after SCT. In 2/6 HA-1 CTL pos patients (patient 5 and 6), HA-1 CTLs disappeared during the observation period on day 450 and 503, respectively.
Relationship between HA-1 CTLs and host chimerism after allogeneic SCT
Commonly applied methods to identify complete donor chimerism as marker of leukemia remission have a sensitivity of detecting 1 host in 10 2 donor cells [5] . In this study, host chime- had host chimerism levels >1% persistently almost throughout an observation period of up to 900 days (patient 7-10; Fig. 1A ). One HA-1 CTL neg patient with persistently high host chimerism levels > 1% showed a rapid decline of host chimerism to undetectable levels after day 900 subsequent to two DLIs (patient 10; Fig. 1A ). Comparison of all samples with both available HA-1 A2 tetramer and host chimerism data revealed that 63/66 HA-1 CTL pos samples had host chimerism levels <1%, while only 23/105 HA-1 CTL neg samples had host chimerism levels <1% (S1 Fig.) . Next, we compared host chimerism levels in samples with and without HA-1 CTLs only at post-transplant time points with ! 4 samples/group (i.e. on day 100, 150 and 250 +/-27) for proper analysis of independent samples at small sample size. Host chimerism values were significantly lower in samples with HA-1 CTLs compared to samples without HA-1 CTLs (p<0.05, two-tailed Mann-Whitney-U-test; Fig. 1B) . Overall, presence of HA-1 CTLs coincided with low host chimerism levels in our cohort.
Isolation and functional characterization of HA-1 CTLs 
HA-1 H CTLs eliminate human hematopoietic stem/progenitor cells in vitro
Next, the capacity of HA-1 CTLs to eliminate human hematopoietic stem/progenitor cells (HSPCs) in vitro was investigated. CD34 + cells were isolated from HLA-A2 + /HA-1 H or HA-1 RR umbilical cord blood (UCBs) and co-incubated overnight with medium, a control CMV CTL clone 5D5, the well defined HA-1 CTL clone 3HA15 isolated after allogeneic SCT [28] and an allo HLA-A2 specific CTL clone MBM13. CD34+ or CD133+ cells were quantified directly after overnight co-incubation, progenitor cells were determined in standard human progenitor cell (HPC) assays after 14 days and presence of stem cells was analyzed in cobblestone area forming cell (CAFC) assays after 5 weeks. Co-incubation of HA-1 RR (i.e. donor type) CD34 + cells with the HA-1 CTL clone resulted in no significant differences in viable CD34 + cell numbers, HPC colonies and CAFC colonies compared to the medium and cytomegalovirus (CMV) CTL control ( Fig. 3A-C) . In contrast, co-incubation of HA-1 H (i.e. patient type) CD34 + cells with the HA-1 CTL clone resulted in a considerable reduction of viable CD34 + cells in the flow cytometry, of particularly CFU-G (granulocyte) and -M (monocyte/macrophage) growth in the HPC assays and of the colony formation in the CAFC assay compared to the medium and CMV CTL control (p<0.05; two-tailed Student's t-test; Fig. 3A-C) . Similar results were obtained after co-incubation of bone marrow (BM) derived HA-1 H CD34 + and CD133 + cells with HA-1 CTLs (Fig. 3D-F CD34+ or CD133+ cells, suppressed HPC growth and entirely prevented colony formation in CAFC assays compared to the medium and CMV CTL control (Fig. 3A-F) (Fig. 3G,H) . The minimum required effector Relationship between HA-1 CTLs and Chimerism to target cell ratio ensuring complete suppression of CAFC colonies was 0.3-1:1. In summary, these data suggest that HA-1 is expressed on human HSPCs and functions as target for HA-1 specific lysis. Fig. 4) . Finally, BM cells of mice sacrificed after 16 weeks were further investigated for the presence of human cells capable of proliferation in progenitor cell assays. In the HALO assay, BM from mice transplanted with CMV CTL treated CD34 + cells showed human cell proliferation, while BM from mice transplanted with HA-1 CTL or with allo-HLA-A2 CTL treated CD34 + cells were negative for human cell proliferation (S2 Fig.) . These data indicate that HA-1 is expressed on human hematopoietic HSPCs with the potential to engraft in NOD/SCID mice.
HA-
Discussion
In this study we investigated for the first time the long term relationship between HA-1 specific immune responses and chimersim after T-cell replete allogeneic HLA-matched HA-1 mismatched SCT. Overall, HA-1 CTLs were detectable in 6/10 patients after T-cell replete HLAmatched, HA-1 mismatched SCT. However, HA-1 CTL numbers were unexpectedly low shortly (i.e. until median day 71) after allogeneic SCT considering the large numbers of HA-1 expressing host hematopoietic cells still present in some patients (patients 1, 2 and 6). The reasons for this observation are unclear. Very large quantity of antigen can suppress antigen specific immune responses [32] . Moreover, HA-1 is also expressed by (hematopoietic) nonantigen presenting cells, such as T-cells, which can be tolerogenic [33] . Thus, the relative overload of mHags presented in a partially tolerogenic context may hamper higher HA-1 CTL expansion shortly after allogeneic SCT. Increasing HA-1 CTLs were measurable at later time points (i.e. after median day 71) subsequent to discontinuation of immune suppression, GvHD or DLI. While HA-1 CTLs during GvHD [25] and subsequent to DLI [20] were described earlier, detection of HA-1 CTLs subsequent to the termination of immune suppression might have been missed in earlier studies because of the T-cell depleted SC grafts. Once detectable, HA-1 CTLs mostly persisted for months or years at low levels in our study. Thus, HA-1 CTLs can create a long lasting immunity after allogeneic SCT. However, for unknown reasons, the HA-1 CTL response terminated in two patients, on days 450 and 503, coinciding with leukemia relapse. It remains to be determined whether the loss of HA-1 CTLs might be associated with specific phenotypic changes, including e.g. differentiation or exhaustion markers that may allow a predication of the termination of the CTL response. HA-1 CTLs were isolated and expanded for functional testing from almost all HA-1 A2 tetra- Relationship between HA-1 CTLs and Chimerism termination of immune suppression (patients 8-10), GvHD (patients 7,10) or DLI (patients 9,10). Thus, neither HA-1 mismatched SCT itself nor the described clinical events are sufficient to evoke detectable HA-1 CTLs. It remains unclear which factors determine presence or absence of HA-1 specific responses after allogeneic SCT. Firstly, pre-immunizations of healthy donors may have an impact [34] , since both mHag sensitization and tolerization can occur through pregnancy in mothers and children [27, 35, 36] . This may involve responses in the mother against mHags inherited only from the father to the child and responses in the child against non-inherited mHags only present in the mother. However, HA-1 CTLs were not detectable in donor PBMC samples in our study, potentially due to the low precursor frequencies of mHag CTLs described earlier [27, 35] . Further studies using larger donor cell numbers are required to understand whether HA-1 specific immunity is transferred from the donor to the patient. Additionally, CD4 T helper cell responses against HLA class II restricted mHag epitopes might enhance HA-1 CTL responses in some patients. However, since only few HLA class II restricted mHags have been identified to date [37, 38] the impact of mHag specific CD4 T helper cell responses of HLA class I restricted mHags can hardly be determined. Finally, host derived professional antigen presenting cells (APCs) surviving conditioning may boost mHag CTL responses after SCT, which might be investigated by simultaneous monitoring of APCs and mHag CTLs [39] . Missing or disappearing mHag CTL responses in some patients in our study might also be explained by immune modulatory effects of leukemia cells suppressing the in vivo expansion of human mHag CTLs [40, 41] . Of note, 2/4 HA-1 CTL negative patients (i.e. patient 7 and 9) were suffering from CLL which can induce T cell exhaustion e.g. via the expression of the ligand to the regulatory T cell surface PD-1 or of immunosuppressive metabolites [40, 41] . Thus, leukemia relapse or persistence may induce loss of donor CTL's, independently of their specific target. Nevertheless, absence of HA-1 CTLs was probably not resulting from a general immune paralysis in our study since CMV and EBV specific CTL responses monitored in separate experiments using fresh blood as described [42] were detectable in the HA-1 CTL negative patients 8 and 9 (S3 Fig.) . The, in our opinion, most interesting and novel observation of the underlying study, is the apparent coincidence of the presence of HA-1 CTLs and the low to undetectable host chimerism levels (detected by highly sensitive quantitative PCR) in most samples throughout the observation period. Nevertheless, presence of HA-1 CTLs early after allogeneic SCT was not predictive for persistent remission. Namely, patients 1, 5 and 6 relapsed despite detectable levels of HA-1 CTLs early after allogeneic SCT. Notably, in the latter two patients samples were available until relapse. In these two patients, functional HA-1 CTLs disappeared later in time which is in accordance with our initial hypothesis that a sustained immune reconstitution with mHag CTLs is required for an ongoing control of the host hematopoiesis including the malignant cells. Accordingly, HA-1 CTL neg patients showed persistently high host chimerism levels after allogeneic SCT. Evidently, if mHag CTLs play a role in the suppression of the host hematopoiesis after allogeneic SCT, this effect will not be restricted to solely HA-1. Namely, only 6.6% (sibling) to 12.0% (matched unrelated donor) of all allogeneic SCTs are performed with an HLA-A2/HA-1 mismatched donor graft [43] . Thus, immune responses against other known and unknown mismatched mHags need to be considered as well. This assumption is supported by the observation in patient 10 who converted to complete donor chimerism after DLIs without detectable HA-1 CTLs. Therefore, we also monitored the anti H-Y immune responses in male patients transplanted with a female donor (patients 3-5; data not shown). Interestingly, anti-HY responses were detectable only in patient 3, i.e. the only patient with grade IV GvHD in our study. This supports our conclusion that presence of a mHag mismatch alone is not sufficient to evoke a mHag specific immune response and that other factors such as GvHD and, potentially, donor pre-immunizations must be considered as well.
Highly sensitive quantitative PCR revealed the persistence of host chimeric cells throughout the post-transplant period in most of the patients in our cohort. Therefore, we raised the question whether HA-1 specific immune responses would be ultimately capable of eradicating the host hematopoiesis. This question becomes increasingly relevant with the use of reduced intensity conditioning where conversion to donor chimerism is considered to be more dependent on immunological factors than after myeloablative regimens [44] . We showed earlier that HA-1 CTLs can eliminate normal and malignant hematopoietic progenitor cells [14] [15] [16] . Obviously, adoptive HA-1 CTL transfer experiments in NOD/SCID mice would be the first choice to demonstrate the effect of HA-1 CTLs against human chimeric hematopoiesis in vivo. However, we previously showed that the in vivo efficacy of HA-1 CTLs -although highly suppressive against human chimeric leukemia cells -is limited in NOD/SCID mice by the short in vivo persistence of the HA-1 CTLs [19] . Therefore, we focused our studies on whether HA-1 is functionally expressed on normal host type hematopoietic HSPCs. HA-1 expression on normal hematopoietic stem cells was suggested earlier. This was based on the observation of host alloreactivity against HA-1 before SCT in patients rejecting their HA-1 mismatched donor graft [45] . In addition to previous reports [14] [15] [16] , HSPCs were derived not only from BM but also from UCB and were further refined by surface expression of CD34 and CD133. Co-incubation of UCB and BM derived CD34 + or CD133 + stem cells with an HA-1 CTL clone established earlier from an allo-transplanted patient [28] abrogated not only HPC formation as described in our previous studies [14] [15] [16] but also CAFC colony formation in vitro. The effect of HA-1 CTLs on UCB derived CD34+ cells and BM derived CD34+ and CD133+ cells was comparable in the 5 week CAFC assays. Importantly, we showed for the first time that HA-1 CTLs prevented hematopoietic repopulation of NOD/SCID mice for at least 16 weeks post transplant indicating that also HSPC with engraftment potential are eliminated by HA-1 CTLs. Evidently, the residual malignant hematopoiesis also contributes to host chimerism in leukemia patients. The HLA-B8 restricted mHag UTY [46] and the HLA-B Ã 2705 restricted mHag DDX3Y [47] are described to be expressed on leukemia stem cells. However, although HA-1 is expressed on virtually all hematological cancers [15] [16] [17] [18] , the formal proof of functional HA-1 expression by malignant stem cells is very cumbersome due to the controversial or still absent characterization of these cells in the various malignancies [48] [49] [50] . Overall, our data show that HA-1 CTLs can specifically destroy normal host type host hematopoietic cells up to the level of HSPCs. This may contribute to the observed coincidence of HA-1 CTLs with mostly very low host hematopoietic cell levels in our study. However, the persistence of host hematopoietic cells in all HA-1 CTL positive patients also indicates that the HA-1 specific immune response emerging after allogeneic SCT is not efficient enough to eradicate the host hematopoiesis. Therefore, we titrated HA-1 CTLs to purified CD34+ and CD133+ cells. Our data indicate that a HA-1 CTL to CD34+ or CD133+ cell ratio of at least 0.3-1:1 within in the stem cell niche would be necessary for the complete eradication of the host hematopoiesis. Considering the overall low frequency of HA-1 CTLs, it appears unlikely, that such high HA-1 CTL numbers at the stem cell niche are achieved in vivo. This leaves the risk of expansion of the normal and malignant host cell compartment at termination of the HA-1 CTLs response.
Conclusions
Our data show in a small patient cohort for the first time that the immune reconstitution with functional CTLs against the mHag HA-1 coincides with low host hematopoiesis levels after Tcell replete HLA-matched, HA-1 mismatched allogeneic SCT. Despite the efficacy of HA-1 CTLs in specifically killing host type hematopoietic cells up to the level of HSPCs, the host hematopoiesis is not completely eradicated by HA-1 CTLs emerging after allogeneic SCT.
Additional studies involving more patients and multiple mismatched mHags are required to confirm the postulated relevance of sustained mHag specific immune responses for the persistence of complete donor chimerism and leukemia remission after allogeneic SCT.
Supporting Information . HLA-A2-restricted CMV (red line) and EBV CTLs (grey line) were detected by tetramer staining of fresh blood as described in [42] . Thus, data cannot be directly compared with the data performed on frozen samples presented in Fig. 1 
